DeSalvo remains committed to health IT

Addressing the federal Health IT Policy Committee at its May 12 meeting, National Coordinator Karen DeSalvo, MD, MPH, MSc, said she would remain in her current position "for some time" as she awaits confirmation by the U.S. Senate for the role of assistant secretary of health.

“I am here today and here in general,” she said. “We have a lot to do still and into the future and I’m looking forward to continuing that pathway with you all.”

DeSalvo said Department of Health and Human Services (HHS) Secretary Sylvia Burwell is committed to the work of the ONC. Burwell “considers the health IT portfolio to be essential to her major initiatives—delivery system reform, precision medicine, and opioids,” according to DeSalvo.

Even if DeSalvo is confirmed for the position, she plans to “continue to be very involved in health information technology” as Burwell’s “senior public health and medicine advisor.”

DeSalvo was named acting assistant secretary for health at HHS to help lead the Obama administration’s Ebola response. She began her role as national coordinator for health IT in January 2014.

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.